CClinicalTrials.gg
CompletedNCT03457883Updated Mar 8, 2018

Risk Factors for Recurrence After Pelvic Reconstruction

An interventional study of herniamesh and biological graft in Pelvic Organ Prolapse, sponsored by Nanjing Medical University. Completed. Open to female participants aged 52 Years to 76 Years. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by Nanjing Medical University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
52 Years to 76 Years
Sex
Female
01

Study summary

232 women underwent transvaginal mesh repair (TVM)with /without transvaginal hysterectomy for symptomatic POP, including group A(accepted herniamesh polypropylene mesh, 117 patients);group B (underwent biological graft of cook,115 patients);follow-ups for six months and one year after the surgery and a questionnaire about the life habits associated with relapse.

Read the detailed description

We prospectively study a total of 232 women who underwent transvaginal mesh repair (TVM)with /without transvaginal hysterectomy for symptomatic POP, the patients into two groups :group A was accepted herniamesh polypropylene mesh(117);group B underwent biological graft of cook(115);Each patient underwent an interview that included a POP-Q which was quantified according to the Pelvic Organ Prolapse Quantitation (POPQ) system;follow-ups for six months and one year after the surgery and a questionnaire about the life habits associated with relapse.

02

Conditions studied

  • Pelvic Organ Prolapse

Keywords

  • Pelvic organ prolapse
  • Vaginal mesh
  • biological graft
  • Recurrence
03

Who can participate

Ages eligible
52 Years to 76 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

242 postmenopausal patients with primary prolapse of the anterior vaginal wall or concomitant uterine prolapse,that was stage Ⅲ or higher (according to the Pelvic Organ Prolapse Quantification [POP-Q] system).

Exclusion criteria

Exclusion Criteria:

pelvic floor repair surgery history and recurrent patients ; pelvic cancer and radiation to the pelvic area in the previous 6 months; simple uterine prolapse; combined with severe stress urinary incontinence or overactive bladder (OAB); local or systemic conditions that would preclude surgery or affect healing such as restricted leg motion (inability to conform to the lithotomy position) ; vaginal bleeding; infection; coagulation disorders; uncontrolled hypertension and diabetes mellitus;

04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    group A

    accepted herniamesh mesh

    Device: herniamesh

  • Experimental
    group B

    accepted biological graft of cook

    Device: biological graft

Interventions

  • Deviceherniamesh

    Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.

  • Devicebiological graft

    Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.

05

What researchers measure

Primary outcomes

  1. recurrence

    Recurrence was defined as a POP-quantification system stage ≥IIb or any symptomatic prolapse.

    Time frame: at 12 months after surgery

Secondary outcomes

  1. perioperative complications

    perioperative complications such as mesh exposure, extrusion , dyspareunia, urinary symptoms(New continence), pain (chronic pelvic pain and hip pain)

    Time frame: 12 months after surgery

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03457883
Lead sponsor
Nanjing Medical University
Responsible party
Xirong Guo (Vice President of Nanjing maternity and child Health Care Hospital, Nanjing Medical University) — Principal investigator
First posted
Mar 8, 2018
Start date
Jan 2015
Primary completion
Jun 2016
Completion
Dec 2017
Last update
Mar 8, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion